HomeCompareAZRX vs GBDC

AZRX vs GBDC: Dividend Comparison 2026

AZRX yields 57.97% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.26M in total portfolio value· pulled ahead in Year 7
10 years
AZRX
AZRX
● Live price
57.97%
Share price
$3.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$589.5K
Annual income
$134,189.34
Full AZRX calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — AZRX vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAZRXGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AZRX + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AZRX pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AZRX
Annual income on $10K today (after 15% tax)
$4,927.54/yr
After 10yr DRIP, annual income (after tax)
$114,060.94/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,869,062.82/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AZRX + GBDC for your $10,000?

AZRX: 50%GBDC: 50%
100% GBDC50/50100% AZRX
Portfolio after 10yr
$10.72M
Annual income
$8,292,461.59/yr
Blended yield
77.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

AZRX
Analyst Ratings
4
Buy
Consensus: Buy
Altman Z
-1.8
Piotroski
6/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AZRX buys
0
GBDC buys
0
No recent congressional trades found for AZRX or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAZRXGBDC
Forward yield57.97%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$589.5K$20.85M
Annual income after 10y$134,189.34$16,450,733.83
Total dividends collected$485.6K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusBuyBuy

Year-by-year: AZRX vs GBDC ($10,000, DRIP)

YearAZRX PortfolioAZRX Income/yrGBDC PortfolioGBDC Income/yrGap
1$16,497$5,797.10$12,492$1,791.70+$4.0KAZRX
2$26,590$8,937.89$16,527$3,160.58+$10.1KAZRX
3$41,915$13,463.51$23,588$5,904.90+$18.3KAZRX
4$64,683$19,834.65$37,141$11,901.65+$27.5KAZRX
5$97,818$28,606.69$66,205$26,463.38+$31.6KAZRX
6$145,096$40,430.56$137,452$66,612.65+$7.6KAZRX
7← crossover$211,301$56,048.29$342,372$195,298.53$131.1KGBDC
8$302,374$76,282.53$1,053,292$686,954.33$750.9KGBDC
9$425,560$102,019.99$4,111,439$2,984,416.95$3.69MGBDC
10$589,539$134,189.34$20,849,974$16,450,733.83$20.26MGBDC

AZRX vs GBDC: Complete Analysis 2026

AZRXStock

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company is headquartered in Brooklyn, New York and currently employs 12 full-time employees. The firm is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The firm's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Full AZRX Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this AZRX vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AZRX vs SCHDAZRX vs JEPIAZRX vs OAZRX vs KOAZRX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.